NEW YORK, March 27-Protein Design Labs hired Brett Schmidli as senior vice president of technical operations, the company said yesterday.
Schmidli will oversee quality and compliance programs, technical development, engineering, and manufacturing as the company scales up toward commercial production. PDL plans to begin building a large manufacturing plant in Minnesota later this year.
Schmidli was most recently director of manufacturing strategy at Eli Lilly. Before that, he was Eli Lilly's chief operating officer and director of commercial development for new antidepressants, and prior to that held a variety of positions in manufacturing and marketing at that firm.
Protein Design Labs, based in Fremont, Calif., develops humanized antibodies.
3rd Millennium vice president of marketing and business development Eric Meyers was promoted to chief operating officer, the company said yesterday.
In this position, Meyers will direct the company's internal growth and supervise new business development, recruitment, and marketing.
Before he joined 3rd Millennium, Meyers was vice president of marketing at health care software firm HealthShare Technology. He also worked in marketing and product management in the Medical Products Group at Hewlett-Packard.
South San Francisco proteomics firm Aspira Biosystems said yesterday that it had hired Michael Nemzek as executive vice president of business development.
Nemzek will direct the company's commercial efforts to apply proteomics to basic research, drug discovery and diagnostics.
He was previously chief business officer at Cellomics, and has also worked at Applied Biosystems, Genosys Biotechnologies, and Tropix, which is now part of Applera.
Aspira's core technology allows for rapid production of sequence-specific capture sites on polymeric beads and arrays.
Bruker AXS said on Monday that Laura Francis will be the company's new chief financial officer as of April 8, 2002. Francis will also direct investor relations for the company.
Francis was mostly recently CFO of start-ups Hypercosm and Nutra-Park. She has also worked as a consultant and manager with McKinsey & Co. and Coopers & Lybrand.
Bruker AXS develops and markets X-ray technology tools for life science and materials research. It is based in Madison, Wis.
Genset said on March 22 that it had appointed company co-founder Marc Vasseur as senior vice president.
Vasseur will direct product development for central nervous system disorders. He reports to Genset president Andre Pernet.
Vasseur co-founded the French genomics company in 1989, and was its chief biology officer until July 2000. He left to found Pasteur Mediavita, a multimedia publishing company focusing on life science and medicine.
Before his tenure at Genset, Vasseur was professor of molecular biology at the University of Paris.
Agencourt Biosciences said on March 21 that it had added Sandra Kay Fisher to its sales force as a senior sales associate.
Fisher will market the company's Solid Phase Reversible Immobilization technology, which allows for sequence tagging of mammalian cDNA by isolating nucleic acids from contaminants.
She will be based in Raleigh, N.C. and will be responsible for marketing in the Southeast and Midatlantic regions
Fisher was previously technical sales consultant at Qiagen, where she sold DNA and RNA extraction products.
Signal transduction scientist Marius Sudol has joined the scientific advisory board of AxCell Biosciences, the company said on March 21. Sudol is expert on the WW protein domain, a major focus of AxCell's research.
Sudol is an associate professor at the Mount Sinai School of Medicine in New York. He is known for characterizing the WW domain, and identifying the role of this module in pathways involved in diseases like muscular dystrophy, Alzheimer's and hypertension.
AxCell Biosciences, based in Newtown, Penn., is a subsidiary of Cytogen.
Aviva Biosciences, a San Diego, Calif.-based biochip company, said on March 21 that it had appointed Eric Lachenmeier as its director of business development.
He will help the firm raise new money and expand its business development.
Lachenmeier was previously founder of a research informatics venture, and was also president of technology development at Incyte Genomics.
Aviva, founded in 1999, is working to develop new high-throughput techniques for biochip-based analyte manipulation and screening.